Jiali Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiali Liu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Adriana C. Vidal
Department of Surgery, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
9 shared publications - Allison Reagan
Division of Urology, Veterans Affairs Health Care System, Durham VA Medical Center, Durham, North Carolina
9 shared publications - Emily Wiggins
Division of Urology, Veterans Affairs Health Care System, Durham VA Medical Center, Durham, North Carolina
9 shared publications - Hemal H. Mehta
Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California
9 shared publications - Jessica L. Janes
Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, USA
9 shared publications - Junxiang Wan
Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA
9 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1040
From Machine Learning-Enhanced Proteomics to a Validated Diagnostic Model: A Pipeline for Breast Cancer Biomarker Discovery via Independent and Transcriptomic Corroboration
Early diagnosis of breast cancer (BC) remains challenging. The limited sensitivity and specificity of existing serum tumor markers for reliable clinical application highlight the need to develop a more accurate and efficient screening workflow. This study analyzed serum samples from 255 breast cancer patients and 300 healthy controls using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, identifying 58 differentially expressed peptides (37 upregulated, 21 downregulated). Combined with machine learning, peptide identification, and external validation, a complete standardized workflow was established. Nine machine learning (ML) algorithms were employed and compared, including SVM, LightGBM, XGBoost, etc. The models were interpreted using SHAP and LIME to identify key features. Peptides of interest were sequenced via mass spectrometry. Their expression and potential prognostic value were further validated in breast cancer transcriptomic datasets. Nine machine learning algorithms showed favorable discriminatory ability in the study cohort. The LightGBM model achieved an AUC of 0.97 internally and maintained an AUC of 0.88, an accuracy of 0.8543, and a precision of 0.9799 externally. However, after correcting for the markedly elevated prevalence (80.3%) in the external cohort, the positive predictive value (PPV) decreased substantially under real-world screening scenarios, warranting prospective validation in true screening populations. Model interpretation and subsequent sequencing identified six core biomarker peptides: Apolipoprotein A-IV (APOA4), Serum Deprivation Response Protein (SDPR), Alpha-1-Antitrypsin (SERPINA1), Ezrin (EZR), Serglycin (SRGN), and Fibrinogen Alpha Chain (FGA). Transcriptomic corroboration suggested that these molecules were significantly dysregulated in breast cancer tissues and showed univariate prognostic associations with patient survival. These findings demonstrated the potential of a proteomics-driven integrated machine learning pipeline as a proof-of-concept auxiliary risk-stratification tool for enhancing early breast cancer diagnosis, warranting further prospective validation in real-world screening cohorts before clinical translation.
- 7 September 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1040
Open AccessFrom Machine Learning-Enhanced Proteomics to a Validated Diagnostic Model: A Pipeline for Breast Cancer Biomarker Discovery via Independent and Transcriptomic Corroboration
Early diagnosis of breast cancer (BC) remains challenging. The limited sensitivity and specificity of existing serum tumor markers for reliable clinical application highlight the need to develop a more accurate and efficient screening workflow. This study analyzed serum samples from 255 breast cancer patients and 300 healthy controls using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, identifying 58 differentially expressed peptides (37 upregulated, 21 downregulated). Combined with machine learning, peptide identification, and external validation, a complete standardized workflow was established. Nine machine learning (ML) algorithms were employed and compared, including SVM, LightGBM, XGBoost, etc. The models were interpreted using SHAP and LIME to identify key features. Peptides of interest were sequenced via mass spectrometry. Their expression and potential prognostic value were further validated in breast cancer transcriptomic datasets. Nine machine learning algorithms showed favorable discriminatory ability in the study cohort. The LightGBM model achieved an AUC of 0.97 internally and maintained an AUC of 0.88, an accuracy of 0.8543, and a precision of 0.9799 externally. However, after correcting for the markedly elevated prevalence (80.3%) in the external cohort, the positive predictive value (PPV) decreased substantially under real-world screening scenarios, warranting prospective validation in true screening populations. Model interpretation and subsequent sequencing identified six core biomarker peptides: Apolipoprotein A-IV (APOA4), Serum Deprivation Response Protein (SDPR), Alpha-1-Antitrypsin (SERPINA1), Ezrin (EZR), Serglycin (SRGN), and Fibrinogen Alpha Chain (FGA). Transcriptomic corroboration suggested that these molecules were significantly dysregulated in breast cancer tissues and showed univariate prognostic associations with patient survival. These findings demonstrated the potential of a proteomics-driven integrated machine learning pipeline as a proof-of-concept auxiliary risk-stratification tool for enhancing early breast cancer diagnosis, warranting further prospective validation in real-world screening cohorts before clinical translation.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S3 shows receiver operating characteristic (ROC) curves between univariable models adjusted for PSA (log-transformed) only, Plasma mtDNA only, and WBC mtDNA only, stratified by Black and White individuals.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S3 shows receiver operating characteristic (ROC) curves between univariable models adjusted for PSA (log-transformed) only, Plasma mtDNA only, and WBC mtDNA only, stratified by Black and White individuals.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S1 shows a comparison of control Mitochondrial DNA copy number levels by BPH status for Black and White individuals
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S1 shows a comparison of control Mitochondrial DNA copy number levels by BPH status for Black and White individuals
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S2 shows the comparison of control Mitochondrial DNA copy number levels in White and Black Individuals
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S2 shows the comparison of control Mitochondrial DNA copy number levels in White and Black Individuals
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S3 shows univariable and multivariable multinomial logistic regression models for testing the association between mtDNA copy number and prostate cancer grade stratified by race
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S3 shows univariable and multivariable multinomial logistic regression models for testing the association between mtDNA copy number and prostate cancer grade stratified by race
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S4 shows a comparison of the distribution of Mitochondrial DNA copy number by prostate cancer grade for Black and White Individuals stratified by plasma and WBC.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S4 shows a comparison of the distribution of Mitochondrial DNA copy number by prostate cancer grade for Black and White Individuals stratified by plasma and WBC.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities.Prevention Relevance:Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities.Prevention Relevance:Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S1 contains mtDNA copy numbers used in this study for Black and White individuals.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S1 contains mtDNA copy numbers used in this study for Black and White individuals.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S2 shows demographic and clinical characteristics at the time of biopsy stratified by prostate cancer grade for all individuals and by race.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S2 shows demographic and clinical characteristics at the time of biopsy stratified by prostate cancer grade for all individuals and by race.
- 13 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (9) , 541-550
Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities. Prevention Relevance: Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.
- 13 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (9) , 541-550
Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities. Prevention Relevance: Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.